Eylea

After Lucentis setback, Novartis trumpets data on follow-up drug

of Lucentis and Eylea for AMD, even though Avastin isn’t approved for the indication. ... Meanwhile, Eylea has been gaining ground in wet AMD thanks to less frequent dosing, accord to GlobalData.

NHS wins legal fight with pharma over off-label Avastin

The two pharma companies mounted the legal challenge to stop the 12 Clinical Commissioning Groups (CCGs) in the north east of England from using Avastin in place of Bayer’s Eylea ... The cost implications are clear, as the court judgement showed: it

Allergan’s abicipar matches AMD blockbuster Lucentis in phase III

Bayer's Eylea remains the drug to beat, however. Allergan has positive phase III results for a wet age-related macular degeneration (AMD) drug that seems to be at least as ... Both studies will continue for another year. Lucentis – sold by Roche in the

Regeneron’s Dupixent and Praluent falls short

Regeneron’s chief executive Len Schleifer said on a conference call that global sales of Eylea were $1.6bn, with Regeneron booking $984m, up 15%. ... Nevertheless, Schleifer told analysts that Dupixent and the immuno-oncology pipeline in particular are

Shaping healthcare

Or with our other big growth product Eylea, a VEGF treatment for the retina, we have 80, 000 patients under treatment as we speak.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]